文献速递造血干细胞移植与细胞治疗

生物标志物指导的α-1抗胰蛋白酶抢先治疗激素难治性GVHD

Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin.
PubMed 文献 · Blood Adv · 2020-01-01

该多中心概念验证试验采用MAGIC算法概率(MAP)在异基因造血干细胞移植后第7天或第14天识别激素难治性急性GVHD高危患者,给予α-1抗胰蛋白酶(AAT)每周两次共16次输注,并与90例高危同期对照比较。

要点

  • 基于第7天或第14天MAP可在移植后早期实时识别激素难治性GVHD高危患者。
  • 该剂量和方案下AAT未能改变激素难治性急性GVHD的发生率。

核心结论

  • 基于生物标志物的实时风险分层在异基因造血干细胞移植后早期可行。
  • 该剂量和方案的AAT未改变激素难治性急性GVHD的发生率。

研究设计与样本

  • 多中心概念验证「抢先」治疗试验,纳入移植后第7天MAP高危或第14天复查转为高危的患者。
  • 试验注册号NCT03459040。

主要发现

  • AAT治疗耐受性良好,毒性反应少。

关键数值与推荐

  • MAP基于血清抑制素2和再生胰岛衍生蛋白3α浓度反映肠道隐窝损伤程度,移植后第7天即可识别激素难治性GVHD高危患者。
  • 高危定义为第7天MAP高危,或初始低危但第14天复查转为高危。
  • AAT给药方案为每周两次输注,共16次。

临床怎么用

  • MAP可在移植后早期实时进行生物标志物风险分层,识别激素难治性GVHD高危患者。
  • 该剂量和方案的AAT不推荐用于降低激素难治性急性GVHD发生率。

局限性

  • 对照组为接近同时期的MAGIC对照患者,非随机同期对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Steroid-refractory (SR) acute graft-versus-host disease (GVHD) remains a major cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT), but its occurrence is not accurately predicted by pre-HCT clinical risk factors. The Mount Sinai Acute GVHD International Consortium (MAGIC) algorithm probability (MAP) identifies patients who are at high risk for developing SR GVHD as early as 7 days after HCT based on the extent of intestinal crypt damage as measured by the concentrations of 2 serum biomarkers, suppressor of tumorigenesis 2 and regenerating islet-derived 3α. We conducted a multicenter proof-of-concept "preemptive" treatment trial of α-1-antitrypsin (AAT), a serine protease inhibitor with demonstrated activity against GVHD, in patients at high risk for developing SR GVHD. Patients were eligible if they possessed a high-risk MAP on day 7 after HCT or, if initially low risk, became high risk on repeat testing at day 14. Thirty high-risk patients were treated with twice-weekly infusions of AAT for a total of 16 doses, and their outcomes were compared with 90 high-risk near-contemporaneous MAGIC control patients. AAT treatment was well tolerated with few toxicities, but it did not lower the incidence of SR GVHD compared with controls (20% vs 14%, P = .56). We conclude that real-time biomarker-based risk assignment is feasible early after allogeneic HCT but that this dose and schedule of AAT did not change the incidence of SR acute GVHD. This trial was registered at www.clinicaltrials.gov as #NCT03459040.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gergoudis SC, DeFilipp Z, Özbek U, et al. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin. Blood Adv. 2020. PMID: 33351103. doi:10.1182/bloodadvances.2020003336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。